Skip to content
AnalystLens

IDEXX Laboratories Quarterly Report for Q1 Ended Mar 31, 2026

Filing Date
Filed May 5, 2026
Period End
March 31, 2026
Security
IDXX
One revenue dollarkept$0.24
In the record · 2016–202610-K1110-Q338-K98

IDXX filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 98 current reports (8-K) between 2016 and 2026.

  1. Leadership change8-K · Feb ’21Feb ’21
  2. Leadership change8-K · Jul ’25Jul ’25

Summary

Summary of the 10-Q filed May 5, 2026. Cited figures are marked; the original filing is the authoritative source.

IDEXX Laboratories, Inc. reported robust financial performance for the first quarter of 2026, demonstrating significant revenue growth and improved profitability.

Total revenue increased by 14.3% year-over-year to $1.14 billiona, driven by strong demand across all operating segments, particularly within the Companion Animal Group (CAG). The company achieved a 15.9% increase in gross profit, expanding the gross profit margin by 100 basis points due to recurring revenue growth, operational efficiencies, and effective price realization, despite inflationary pressures. Net income saw a substantial rise of 14.8% to $278.4 million, translating to diluted earnings per share of $3.47, up from $2.96 in the prior year.

The company's balance sheet remains solid with $200.5 millionb in cash and cash equivalents and $718.2 million in available borrowing capacity under its credit facility. Significant stock repurchase activity continued, reflecting a commitment to returning value to shareholders. The company provided a positive outlook, anticipating favorable currency impacts for the remainder of the year.

Key Highlights

  1. Total revenue increased by 14.3% to $1.14 billion, driven by broad-based growth across segments, especially CAG.
  2. Gross profit grew by 15.9% to $722.7 million, with a gross profit margin expansion of 100 basis points to 63.4%.
  3. Net income rose 14.8% to $278.4 million, with diluted EPS improving to $3.47 from $2.96 year-over-year.
  4. Strong performance in CAG Diagnostics recurring revenue, including VetLab consumables and reference laboratory services, with organic growth of 11.0% and 11.6% respectively.
  5. Cash flows from operations improved by $28.3 million to $266.2 million, demonstrating healthy operational cash generation.
  6. The company maintained a strong liquidity position with $200.5 million in cash and cash equivalents and significant availability under its credit facility.
  7. Continued aggressive share repurchase program, with $360.8 million spent on open market repurchases during the quarter.

Follow one dollar

Of each $1.00 of revenue in Q1 FY2026, IDEXX Laboratories kept $0.24.

  1. Revenue$1.14B100.0%
  2. Cost of revenue−$418.1M36.6%
  3. Gross profit$722.7M63.4%
  4. Operating costs−$360.2M31.6%
  5. Operating income$362.6M31.8%
  6. Interest, other & tax−$84.1M7.4%
  7. Net income$278.4M24.4%
Computed from 10-QQ1 FY2026filed May 5, 2026Computed from this filing’s revenue, gross profit, operating income and net income · right columngrey figure: share of revenue

Financial Statements

Q1 FY2026 against Q1 FY2025

Line itemQ1 FY2026Q1 FY2025Change
Revenue$1.14B$998.43M+14.3%
Cost of Revenue$418.08M$375.05M+11.5%
Gross Profit$722.74M$623.38M+15.9%
R&D Expenses$65.79M$59.06M+11.4%
Operating Expenses$360.15M$306.85M+17.4%
Operating Income$362.59M$316.53M+14.5%
Net Income$278.45M$242.68M+14.7%
EPS (Basic)$3.50$2.98+17.4%
EPS (Diluted)$3.47$2.96+17.2%
Shares Outstanding (Basic)79.65M81.32M−2.1%
Shares Outstanding (Diluted)80.16M81.92M−2.1%

Frequently Asked Questions

  1. What were the primary drivers of IDEXX's revenue growth in the first quarter of 2026?

    Revenue growth was primarily driven by strong demand in the Companion Animal Group (CAG), particularly in CAG Diagnostics recurring revenue streams like IDEXX VetLab consumables and reference laboratory services. Higher volumes and realized prices across all segments, along with new business gains and customer retention, were key contributors.

  2. How did IDEXX manage its profitability despite inflationary pressures?

    IDEXX expanded its gross profit margin by 100 basis points to 63.4%. This was achieved through benefits from recurring revenue growth, operational productivity improvements, and net price realization. While inflationary costs and investments presented challenges, these were effectively managed to allow for margin expansion.

  3. What is the company's financial outlook for the remainder of 2026 regarding currency impacts?

    IDEXX anticipates favorable year-over-year currency impacts for the remainder of 2026, projecting an increase in revenues, operating profit, and diluted earnings per share. This outlook includes expected net year-over-year impacts from foreign currency hedging activity.

  4. How is IDEXX managing its debt obligations, particularly the upcoming maturities?

    IDEXX has sufficient resources to meet its upcoming debt obligations, including the $75 million in Senior Notes due September 4, 2026, and the $75 million in 2027 Series B Notes due February 12, 2027. They anticipate funding these repayments with available cash on hand, borrowings under their Credit Facility, or proceeds from new note issuances.